You might also like
Champions Oncology, Inc. (CSBR) is a technology-enabled research organization specializing in oncology drug discovery and development. The company provides innovative research services, oncology research software tools, and develops novel oncology therapeutics. CSBR leverages advanced platforms, including a TumorGraft technology platform and a comprehensive Datacenter, to assist pharmaceutical and biotechnology companies in accelerating drug development and improving therapeutic outcomes.
- Research Services - Offers in vivo and ex vivo studies, bioinformatics analysis, and computational or experimental support for drug development, utilizing their TumorGraft technology platform to predict the efficacy of oncology drugs.
- Oncology Research SaaS Tools - Provides oncology data-driven software, such as Lumin Bioinformatics, which uses analytics and artificial intelligence to support cancer research and drug discovery.
- License Revenue - Sells licenses for access to proprietary Patient Derived Xenograft (PDX) data, enabling researchers to utilize unique datasets for oncology studies.
- Personalized Oncology Services - Focuses on personalized approaches to cancer treatment, though this segment currently has minimal or no revenue contribution.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Joel Ackerman ExecutiveBoard | Chairman of the Board | CFO of Davita, Inc. | Joel Ackerman has served as the Chairman of the Board of Champions Oncology, Inc. since January 2017 after previously serving as the CEO and a director from October 2010 to January 2017. He also holds an external executive role as CFO of Davita, Inc.. | |
Ronnie Morris ExecutiveBoard | Chief Executive Officer (CEO) | Ronnie Morris, M.D. is the CEO of Champions Oncology since January 2017. He has served on the Board of Directors since October 2010 and previously held the role of President from October 2010 until January 2017. | View Report → | |
David Miller Executive | Chief Financial Officer (CFO) | Chief Financial Officer at Champions Oncology, Inc. since May 2017, previously served as Vice President, Finance from June 2013 to April 2017. | ||
Matt Newman Executive | Executive Vice President and General Manager | Matt Newman is the Executive Vice President and General Manager at CSBR, hired to lead the development of the company’s data licensing platform during the third quarter of fiscal 2025 (ended January 31, 2025). There is no additional information on board or other appointments. | ||
Daniel Mendelson Board | Director | CEO of Morgan Health; Adjunct Professor at Georgetown University; Board Member at Vera Whole Health; Board Member at Alliance for Health Policy | Daniel Mendelson has served as Director at CSBR since March 2013, bringing extensive experience from leadership roles in healthcare and government. He has held executive positions such as CEO of Morgan Health and has contributed as an adjunct professor and board member at other organizations. | |
David Sidransky Board | Lead Director | Chairman of the Board at Ayala Pharmaceuticals and Advaxis Immunotherapies; Board member of Galmed, Ascentage, and Orgenesis | Dr. Sidransky has served as a director at CSBR since August 2007 and as Lead Director since November 2016, and is renowned for his distinguished contributions in oncology and biotechnology. | |
Philip Breitfeld Board | Director | Chief Medical Officer at Allterum Therapeutics; Member of the Scientific Advisory Board at MMS | Philip Breitfeld, M.D., has served as a Director of Champions Oncology, Inc. since April 2016. He brings extensive experience in clinical oncology, having held roles such as Chief Medical Officer at Allterum Therapeutics and Global Vice President at Quintiles. | |
Robert Brainin Board | Director | Executive Vice President and Chief Business Officer at Veracyte ; Board Member at The Children's Tumor Foundation | Robert Brainin has served as a Director at CSBR since February 2021. He brings extensive leadership experience from roles such as Executive Vice President and Chief Business Officer at Veracyte since July 2021. | |
Scott R. Tobin Board | Director | Senior Partner at Battery Ventures; Managing Partner at Battery Ventures funds | Scott R. Tobin has served as a Director at Champions Oncology (CSBR) since June 2011 and currently serves as the Chairperson of the Audit Committee, overseeing accounting, financial reporting, internal controls, and compliance. Outside of CSBR, he is a Senior Partner at Battery Ventures, and has been a Managing Partner of various funds since May 2000. |
- Given the successful one-time data licensing deal, can you clarify how this deal shapes your future strategy for recurring revenue models and whether there are plans to standardize pricing across different customer segments?
- With the observed volatility in the biotech sector due to market conditions and potential tariff impacts, how do you intend to safeguard your core research service revenue and manage cost pressures moving forward?
- In light of the spin-out of your drug development subsidiary and the ongoing capital raise, how will the funding structure and associated milestones impact the parent company's balance sheet and overall capital allocation?
- As AI capabilities become increasingly critical to extract insights from your deep multiomic data, what specific investments or partnerships are being pursued to accelerate the application of AI in both drug discovery and potential biomarker development?
- Considering the competitive landscape with numerous entities selling broader data sets, how do you plan to defend your differentiated, deep-data approach and expand your data licensing pipeline against established players?
Recent press releases and 8-K filings for CSBR.
- Champions Oncology, Inc. reported record Q3 2025 revenue of $17.0 million (a 42% increase), with record adjusted EBITDA of $5.2 million and GAAP operating income/net income of approximately $4.5 million
- Data Licensing Initiative: Secured its first major, one-time data licensing deal valued up to $8.0 million, contributing $4.5 million in data revenue
- Operational Efficiency and Guidance: Improved cost management and research services boosted performance to achieve 61% gross margins, ending the quarter with $3.2 million in cash and no debt, while reaffirming full-year revenue growth guidance of 10%-15%